260 related articles for article (PubMed ID: 35196808)
1. Evaluation of the Levels of Peripheral CD3
Aljabr W; Al-Amari A; Abbas B; Karkashan A; Alamri S; Alnamnakani M; Al-Qahtani A
Microbiol Spectr; 2022 Feb; 10(1):e0084521. PubMed ID: 35196808
[TBL] [Abstract][Full Text] [Related]
2. Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities.
Orner EP; Rodgers MA; Hock K; Tang MS; Taylor R; Gardiner M; Olivo A; Fox A; Prostko J; Cloherty G; Farnsworth CW
Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115300. PubMed ID: 33388575
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of commercially available immuno-magnetic agglutination in comparison to enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19.
Moeller ME; Fock J; Pah P; Veras AC; Bade M; Donolato M; Israelsen SB; Eugen-Olsen J; Benfield T; Engsig FN
J Med Virol; 2021 May; 93(5):3084-3091. PubMed ID: 33547818
[TBL] [Abstract][Full Text] [Related]
4. Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques.
Hasenkrug KJ; Feldmann F; Myers L; Santiago ML; Guo K; Barrett BS; Mickens KL; Carmody A; Okumura A; Rao D; Collins MM; Messer RJ; Lovaglio J; Shaia C; Rosenke R; van Doremalen N; Clancy C; Saturday G; Hanley P; Smith BJ; Meade-White K; Shupert WL; Hawman DW; Feldmann H
mBio; 2021 Aug; 12(4):e0150321. PubMed ID: 34311582
[TBL] [Abstract][Full Text] [Related]
5. Immune cell profiling and antibody responses in patients with COVID-19.
Rezaei M; Mahmoudi S; Mortaz E; Marjani M
BMC Infect Dis; 2021 Jul; 21(1):646. PubMed ID: 34225645
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus.
Casado-Fernández G; Cantón J; Nasarre L; Ramos-Martín F; Manzanares M; Sánchez-Menéndez C; Fuertes D; Mateos E; Murciano-Antón MA; Pérez-Olmeda M; Cervero M; Torres M; Rodríguez-Rosado R; Coiras M
Front Immunol; 2024; 15():1362621. PubMed ID: 38812512
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Observation of Immune Response for 23 Months in COVID-19 Convalescent Patients After Infection and Vaccination.
Xu J; Zheng J; Tan Y; Cai J; Xiang Y; Ling H; Li Z; Bai Q
Viral Immunol; 2023; 36(6):389-400. PubMed ID: 37276049
[TBL] [Abstract][Full Text] [Related]
8. Antibody Responses in COVID-19: A Review.
Chvatal-Medina M; Mendez-Cortina Y; Patiño PJ; Velilla PA; Rugeles MT
Front Immunol; 2021; 12():633184. PubMed ID: 33936045
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses.
Vibholm LK; Nielsen SSF; Pahus MH; Frattari GS; Olesen R; Andersen R; Monrad I; Andersen AHF; Thomsen MM; Konrad CV; Andersen SD; Højen JF; Gunst JD; Østergaard L; Søgaard OS; Schleimann MH; Tolstrup M
EBioMedicine; 2021 Feb; 64():103230. PubMed ID: 33530000
[TBL] [Abstract][Full Text] [Related]
10. Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination.
Leacy EJ; Teh JW; O'Rourke AM; Brady G; Gargan S; Conlon N; Scott J; Dunne J; Phelan T; Griffin MD; Power J; Mooney A; Naughton A; Kiersey R; Gardiner M; O'Brien C; Mullan R; Flood R; Clarkson M; Townsend L; O'Shaughnessy M; Dyer AH; Moran B; Fletcher JM; Zgaga L; Little MA;
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791279
[TBL] [Abstract][Full Text] [Related]
11. Serum AXL is a potential molecular marker for predicting COVID-19 progression.
You J; Huang R; Zhong R; Shen J; Huang S; Chen J; Chen F; Kang Y; Chen L
Front Immunol; 2024; 15():1394429. PubMed ID: 38799467
[TBL] [Abstract][Full Text] [Related]
12. IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Staines HM; Kirwan DE; Clark DJ; Adams ER; Augustin Y; Byrne RL; Cocozza M; Cubas-Atienzar AI; Cuevas LE; Cusinato M; Davies BMO; Davis M; Davis P; Duvoix A; Eckersley NM; Forton D; Fraser AJ; Garrod G; Hadcocks L; Hu Q; Johnson M; Kay GA; Klekotko K; Lewis Z; Macallan DC; Mensah-Kane J; Menzies S; Monahan I; Moore CM; Nebe-von-Caron G; Owen SI; Sainter C; Sall AA; Schouten J; Williams CT; Wilkins J; Woolston K; Fitchett JRA; Krishna S; Planche T
Emerg Infect Dis; 2021 Jan; 27(1):85-91. PubMed ID: 33256890
[TBL] [Abstract][Full Text] [Related]
13. Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients.
Ni L; Cheng ML; Feng Y; Zhao H; Liu J; Ye F; Ye Q; Zhu G; Li X; Wang P; Shao J; Deng YQ; Wei P; Chen F; Qin CF; Wang G; Li F; Zeng H; Dong C
Front Immunol; 2021; 12():603563. PubMed ID: 33603759
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment.
Liu J; Yang X; Wang H; Li Z; Deng H; Liu J; Xiong S; He J; Feng X; Guo C; Wang W; Zelinskyy G; Trilling M; Sutter K; Senff T; Menne C; Timm J; Zhang Y; Deng F; Lu Y; Wu J; Lu M; Yang D; Dittmer U; Wang B; Zheng X
mBio; 2021 Apr; 12(2):. PubMed ID: 33906918
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection.
Orologas-Stavrou N; Politou M; Rousakis P; Kostopoulos IV; Ntanasis-Stathopoulos I; Jahaj E; Tsiligkeridou E; Gavriatopoulou M; Kastritis E; Kotanidou A; Dimopoulos MA; Tsitsilonis OE; Terpos E
Viruses; 2020 Dec; 13(1):. PubMed ID: 33375675
[TBL] [Abstract][Full Text] [Related]
16. Improving the Understanding of the Immunopathogenesis of Lymphopenia as a Correlate of SARS-CoV-2 Infection Risk and Disease Progression in African Patients: Protocol for a Cross-sectional Study.
Iwalokun BA; Olalekan A; Adenipekun E; Ojo O; Iwalokun SO; Mutiu B; Orija O; Adegbola R; Salako B; Akinloye O
JMIR Res Protoc; 2021 Mar; 10(3):e21242. PubMed ID: 33621190
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing immunity to SARS-CoV-2 before the COVID-19 pandemic era in Cameroon: A comparative analysis according to HIV-status.
Aissatou A; Fokam J; Semengue ENJ; Takou D; Ka'e AC; Ambe CC; Nka AD; Djupsa SC; Beloumou G; Ciaffi L; Tchouaket MCT; Nayang ARM; Pabo WLT; Essomba RG; Halle EGE; Okomo MC; Bissek AZ; Leke R; Boum Y; Mballa GAE; Montesano C; Perno CF; Colizzi V; Ndjolo A
Front Immunol; 2023; 14():1155855. PubMed ID: 37090738
[TBL] [Abstract][Full Text] [Related]
18. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients.
Wang Y; Li J; Li H; Lei P; Shen G; Yang C
Int Immunopharmacol; 2021 Jan; 90():107271. PubMed ID: 33310664
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte B Subtypes in Peripheral Blood: A Prognostic Biomarker for COVID-19 Patients.
Felisberto M; Walter LO; Cardoso CC; Santos-Pirath ÍM; Costa HZ; Gartner R; Werle I; Mohr ETB; Salvan da Rosa J; Lubschinski TL; Kretzer IF; Masukawa II; de Almeida Vanny P; Luiz MC; Rabello de Moraes AC; Santos-Silva MC; Dalmarco EM
J Appl Lab Med; 2024 May; 9(3):456-467. PubMed ID: 38321537
[TBL] [Abstract][Full Text] [Related]
20. T-cell responses in COVID-19 survivors 6-8 months after infection: A longitudinal cohort study in Pune.
Suryawanshi P; Patil-Takbhate B; Athavale P; Mirza S; Tripathy A; Kanitkar S; Shivnitwar S; Barthwal MS; Dole S; Chavan H; Jali P; Pawale S; Kakad D; Kakrani AL; Bhawalkar J; Gandhi M; Chaturvedi S; Karandikar M; Tripathy S
Immun Inflamm Dis; 2024 Jun; 12(6):e1238. PubMed ID: 38860770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
